Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-04-30

Clinical Trial Update: Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating antiangiogenic therapy with bevacizumab and everolimus for hepatocellular carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • Everolimus (everolimus)

Snippet

Sponsor: Gerhard Treiber | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED